



ASX Announcement

19 March 2025

Wellnex Life Limited publishes Admission Document for admission to the AIM market of the London Stock Exchange

- Wellnex Life has published an Admission Document for its dual listing on the AIM market of the London Stock Exchange, with admission expected on Friday 21 March 2025.
- The dual listing on the AIM market is a pivotal moment for Wellnex Life that will assist in continuing the Company's growth in the consumer healthcare market.
- Concurrent with admission to the AIM market, Wellnex Life will extinguish the material deferred consideration for the Pain Away acquisition and the outstanding Convertible Notes totaling, in aggregate, \$11.9 million, saving the Company \$1.4 million annually in interest costs and fees significantly improving the Company's balance sheet.

Wellnex Life Limited (ASX: WNX) ("**Wellnex Life**" or the "**Company**") is pleased to announce it has published its Admission Document for the dual listing on the AIM market (AIM) of the London Stock Exchange (LSE).

The publication of the [Admission Document](#) is a key step for admission to AIM, with trading on AIM expected to commence at 8.00 a.m. on 21 March 2025 (UK time).

The dual listing on the LSE is a pivotal moment for Wellnex Life that will assist the Company with its growth plans, by taking advantage of the growing consumer healthcare market both in Australia and globally.

Wellnex Life, with its innovative brands and products, is well positioned to take advantage of these opportunities as evidenced by the recent launch of its products in the UK under the Company's supply agreement with Haleon.

Wellnex Life, on admission to AIM will be able to extinguish \$11.9 million in debt in the form of the material deferred consideration for the acquisition of Pain Away and the outstanding Convertible Notes. This will not only save the company \$1.4 million in annual interest costs and fees but will provide the Company with a balance sheet that will support the future growth plans for the business.

Zack Bozinovski, Managing Director of Wellnex Life said "The publication of the Admission Document and the imminent admission to AIM, will not only save the company \$1.4 million through the elimination of circa \$11.9 million in debt, but it will also provide increased exposure and credibility to the Company as it launches its brands into the European market. This follows the UK launch, with Haleon, of our innovative liquid paracetamol soft gel. Wellnex Life has a



strong brand and product portfolio, and with a strengthened balance sheet, I am confident that it will have the necessary platform from which to grow revenues and margins.”

Investors should be aware that the Admission Document does not constitute an offer to any persons other than those expressly set out in the Admission Document. In particular the Admission Document does not constitute an offer of the Company’s shares to persons who would require a disclosure document under the Corporations Act.

To stay up to date on Company news and announcements, please register your details on the Wellnex Life Limited investor portal: <https://wellnexlife.investorportal.com.au/register/>

This announcement was authorised for release to the market by the board of Wellnex Life Limited.

For further information, please contact:

Reach Markets

T: 1300 805 795

E: IR@reachmarkets.com.au